Teva Pharmaceutical Industries Ltd Receives Consensus Rating of “Buy” from Analysts (NASDAQ:TEVA)
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) have received an average recommendation of “Buy” from the twenty-five analysts that are covering the stock, StockRatingsNetwork reports. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $58.39.
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) opened at 53.45 on Thursday. Teva Pharmaceutical Industries Ltd has a 52 week low of $36.26 and a 52 week high of $55.70. The stock has a 50-day moving average of $53.37 and a 200-day moving average of $50.87. The company has a market cap of $45.630 billion and a P/E ratio of 17.66.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last released its earnings data on Thursday, July 31st. The company reported $1.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.21 by $0.02. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter last year, the company posted $1.20 earnings per share. Teva Pharmaceutical Industries Ltd’s revenue was up 2.5% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Ltd will post $4.94 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, September 4th. Stockholders of record on Thursday, August 21st will be given a dividend of $0.353 per share. This represents a $1.41 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date of this dividend is Tuesday, August 19th.
TEVA has been the subject of a number of recent research reports. Analysts at Maxim Group initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, August 5th. They set a “buy” rating and a $62.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Monday, August 4th. They now have a $57.00 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Teva Pharmaceutical Industries Ltd from $55.70 to $58.00 in a research note on Friday, August 1st. They now have a “hold” rating on the stock.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.